Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy

被引：0

作者：

Corso, Alessandro ^{[1
]}

Barbarano, Luciana ^{[2
]}

Mangiacavalli, Silvia ^{[1
]}

Montalbetti, Luigi

Brasca, Paola ^{[2
]}

Zappasodi, Patrizia ^{[1
]}

Carella, Angelo ^{[3
]}

Spriano, Mauro ^{[3
]}

Alessandrino, Emilio Paolo ^{[1
]}

Cairoli, Roberto ^{[2
]}

Petro, Daniela ^{[2
]}

Varettoni, Marzia ^{[1
]}

Bernasconi, Paolo ^{[1
]}

Lazzarino, Mario ^{[1
]}

Morra, Enrica ^{[2
]}

机构：

[1] Univ Pavia, Fdn IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy

[2] Osped Ca Granda, Div Hematol, Milan, Italy

[3] Osped San Martino Genova, Div Hematol, Genoa, Italy

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3595

引用

页码：1051A / 1052A

页数：2

共 50 条

[21] Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma
Chiharu I. Kobayashi
Go Yamamoto
Akimasa Hayashi
Satoshi Ota
Yoichi Imai
Masashi Fukayama
Mineo Kurokawa
Annals of Hematology, 2011, 90 : 225 - 226
[22] Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma
Kobayashi, Chiharu I.
Yamamoto, Go
Hayashi, Akimasa
Ota, Satoshi
Imai, Yoichi
Fukayama, Masashi
Kurokawa, Mineo
ANNALS OF HEMATOLOGY, 2011, 90 (02) : 225 - 226
[23] Impact of low-dose thalidomide as maintenance therapy in advanced multiple myeloma patients following high-dose therapy
Andreini, A.
Ruggeri, G.
Sorio, M.
Tecchio, C.
Frattini, F.
Ledro, S.
Perbellini, C.
de Sabata, D.
Quaresmini, G.
Benedetti, F.
BONE MARROW TRANSPLANTATION, 2010, 45 : S149 - S149
[24] Impact of low-dose thalidomide as maintenance therapy in advanced multiple myeloma patients following high-dose therapy
Andreini, A.
Randon, F.
Tecchio, C.
Quaresmini, G.
Frattini, F.
Di Bella, R.
Sorio, M.
Ledro, S.
Perbellini, C.
de Sabata, D.
Benedetti, F.
BONE MARROW TRANSPLANTATION, 2009, 43 : S152 - S152
[25] Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma
Fenk, Roland
Baier, Julia
Giagounidis, Aristoteles
Rummel, Mathias J.
Kroeger, Nicolaus
Strapatsas, Tobias
Dienst, Ariane
Zipperer, Esther
Nachtkamp, Kathrin
Burchardt, Alexander
Schroeder, Thomas
Galonska, Lars
Gattermann, Norbert
Haas, Rainer
Kobbe, Guido
BLOOD, 2012, 120 (21)
[26] Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
Nucci, Marcio
Anaissie, Elias
CLINICAL INFECTIOUS DISEASES, 2009, 49 (08) : 1211 - 1225
[27] Risk driven decision for high-dose therapy in multiple myeloma - No
Goldschmidt, H.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 242 - 242
[28] AN INCREMENTAL RESPONSE TO HIGH-DOSE THERAPY IN MULTIPLE-MYELOMA
HAWKINS, T
HORVATH, N
RAWLING, C
BAYLY, J
ANDARY, V
DYSON, P
HO, J
DART, G
JUTTNER, C
TO, L
EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 759 - 759
[29] High-dose therapy and innovative approaches to treatment of multiple myeloma
Barlogie, B
SEMINARS IN HEMATOLOGY, 2001, 38 (02) : 21 - 27
[30] High-dose therapy in multiple myeloma and primary amyloidosis: An overview
Kyle, RA
SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 83

← 1 2 3 4 5 →